Engflag

Synaleve

Quick links to important sections

Synaleve

Synaleve_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synaleve

Property Description
Active Ingredients Acetaminophen, Codeine Phosphate, Meprobamate
Form Tablet or Capsule (Oral Administration)
Pharmacological Class Combination Analgesic, Anxiolytic
Common Use Relief of pain associated with anxiety
Origin Synthetic (Derived Chemical Substances)

What Type of Medicine is Synaleve?

Synaleve is a prescription-only medicine and a fixed-dose combination product primarily classified as a polycomponent analgesic with an added anxiolytic function. This unique classification is necessary because its composition operates across multiple pharmacological categories, distinguishing it from simple binary pain relievers. The inclusion of the mu-opioid analgesic Codeine, one of the components, is clinically recognized for its ability to moderate pain perception in the Central Nervous System (CNS).

Synaleve Composition and Origin

Synaleve is a synthetic compound typically prepared for oral administration in the dosage form of a tablet or capsule. Its formulation includes the non-opioid analgesic Acetaminophen (or Paracetamol), the opioid analgesic Codeine Phosphate, and the carbamate derivative and minor tranquilizer Meprobamate. Meprobamate, the component providing the calming effect, is a compound historically supported by pharmacological studies for its anxiolytic properties. The combination is specifically designed to integrate the strong pain-relief properties of Acetaminophen and Codeine with the sedative and anxiety-reducing effects of Meprobamate within a solid pharmaceutical base, making it a unique solution compared to non-anxiolytic pain combinations.

General Therapeutic Purpose

The general therapeutic purpose of Synaleve is to provide integrated relief by simultaneously treating the physical sensation of pain and the psychological distress often associated with it, such as muscle tension. This is achieved through the pharmacodynamic synergism of its components, where the strong analgesic effect is complemented by an anxiolytic effect to mitigate anxiety. For example, the medicine may be used when a patient experiences moderate to severe pain that is intensified by concurrent stress or apprehension. This dual action is the key differentiating factor, making the product highly specific for pain conditions where emotional or stress factors are significant contributors.

What side effects are possible with Synaleve?

Possible Side Effects and Safety Information

The officially documented safety profile for Synaleve is structured around risks to the central nervous system, potential for dependence, and rare but severe systemic reactions, based on regulatory evaluations.

Adverse Reaction Categories

Classification Examples of Reactions
Very Common Drowsiness, dizziness, unsteadiness
Common Headache, nausea, vomiting, constipation, euphoria
Uncommon Confusion, insomnia, dry mouth, blurred vision, allergic skin reactions

Serious and Clinically Significant Safety Risks

Official regulatory documents emphasize the following serious adverse reactions and safety considerations:

  • Serious CNS Risks and Overdose: Government health authorities note the risk of profound sedation, respiratory depression, coma, and death, which can occur even at therapeutic doses. This risk is heightened due to the small difference between the effective dose and the potentially fatal overdose amount.
  • Dependence and Withdrawal: The drug carries a significant risk of developing physical and psychological dependence and abuse. Abrupt discontinuation after prolonged use may lead to severe withdrawal symptoms, including seizures.
  • Rare Systemic Adverse Reactions: Documented adverse events include rare but serious effects on the blood and immune system, such as agranulocytosis, aplastic anemia, and severe cutaneous hypersensitivity reactions (e.g., Stevens-Johnson syndrome, anaphylaxis).
  • Drug Interactions: The effects of the medicine are additive with other central nervous system (CNS) depressants, including alcohol, which significantly increases the danger of profound sedation and respiratory depression.
  • Population-Specific: The elderly population may experience increased sensitivity to side effects like drowsiness and are at a higher risk of confusion and overdose. Caution is also noted for patients with impaired respiratory or hepatic function.

This structure reflects the regulatory finding that the risks associated with CNS depression and dependence constitute a major part of the drug’s official safety profile, requiring specific warnings and limitations on use.

Overdose and Emergency Response

Synaleve overdose involves the combined toxic effects of its three components, presenting an immediate risk of acute Central Nervous System (CNS) depression and a delayed risk of severe liver damage. Documented manifestations reflect this dual risk.

Acute signs include symptoms related to CNS and respiratory depression, such as drowsiness, stupor, confusion, and pinpoint pupils. Severe, life-threatening outcomes reported in regulatory documents are respiratory collapse, shock, and the progression to coma. Due to the Acetaminophen component, a severe, delayed manifestation is hepatic failure or liver necrosis, which can be fatal. Early signs of liver toxicity may include nausea, vomiting, and pallor, but clinical evidence of damage may not appear until 48 to 72 hours after ingestion.

Immediate medical attention must be sought for any known or suspected overdose, even if the individual appears asymptomatic. Regulatory guidance prioritizes the reestablishment of a patent airway and the institution of assisted or controlled ventilation. Management involves supportive care and the administration of the two specific antidotes documented in official labeling: Naloxone for opioid effects and N-acetylcysteine for Acetaminophen toxicity. Monitoring requires tracking vital signs and conducting specific laboratory tests, including serum Acetaminophen concentration and hepatic function studies.

Therapeutic Uses of Synaleve

What Synaleve Treats: Main Uses and Benefits

Synaleve is commonly used to help address symptoms related to physical discomfort (such as moderate to severe pain) in situations where patients experience associated anxiety or apprehension. Its anxiolytic component is generally applied for the short-term relief of anxiety symptoms. This combination is relevant for easing symptoms related to physical discomfort and associated psychological distress, which contributes to easing the overall symptom load when emotional tension is present.

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as managing postoperative or post-traumatic discomfort, and is applied during phases when symptoms become more noticeable. Indications that may be part of symptomatic management include acute episodes of pain where emotional factors are present, and conditions presenting with significant musculoskeletal discomfort. It is used for managing symptoms that are pronounced and difficult to tolerate.

“The primary benefit is providing short-term symptomatic assistance that may assist with maintaining a sense of stability during challenging manifestations.”

Quick Fact: Relief for Pain with Tension

The core therapeutic purpose is the relief provided for symptoms related to physical discomfort and the accompanying psychological stress, which supports general well-being.

Regulatory References

  1. DailyMed Overview of Meprobamate Therapeutic Use

Eligibility and Restrictions for Use

Eligibility for Synaleve: Official Regulatory Rules

Synaleve's eligibility is strictly defined by regulatory authorities due to its components: Acetaminophen, Codeine, and Meprobamate. Official labeling establishes formal prohibitions and special restrictions based on patient population, age, and clinical status. The medicine is generally intended for adults (18 to 64 years) for short-term management under standard labeled conditions.

Absolute Contraindications

The medicine is contraindicated (must not be used) in the following groups:

  • Children under 12 years of age.
  • Breastfeeding mothers (due to the risk profile of Codeine).
  • Patients with Severe Hepatic Impairment or Active Liver Disease.
  • Patients with acute or severe respiratory depression or gastrointestinal obstruction (including paralytic ileus).
  • Adolescents (12–18 years) who have undergone tonsillectomy or adenoidectomy.
  • Patients identified as CYP2D6 ultra-rapid metabolizers or those with acute intermittent porphyria.

Restrictions and Conditional Use

Official documents mandate special caution or restriction for certain patient populations:

  • Older adults (≥65 years): Use requires caution, often starting with the lowest effective dose.
  • Severe Renal Impairment: Requires extreme caution due to the potential for metabolite accumulation.
  • Patients with a history of substance abuse or opioid dependence: Use requires extreme caution due to the high abuse potential of the opioid and anxiolytic components.
  • Pregnancy: Use is not recommended in the third trimester due to the risk of Neonatal Opioid Withdrawal Syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

  • Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Serotonergic Drugs, Opioid Antagonists, CYP450 Enzyme Modulators, and Coumarin Anticoagulants.
  • Specific interacting medicines (if explicitly listed): Warfarin and specific CYP inhibitors such as quinidine are cited in regulatory documentation.
  • Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction via inhibition or induction of cytochrome P450 enzymes (CYP2D6, CYP3A4) for the Codeine component; Pharmacodynamic interaction leading to additive CNS depression for Codeine and Meprobamate; alteration of the International Normalized Ratio (INR) by the Acetaminophen component.
  • Timing-based interaction rules (if applicable): Co-administration with MAOIs is formally prohibited within 14 days of discontinuing the MAOI. Cholestyramine administration is suggested to be separated from Acetaminophen by at least 1 hour.
  • Population-specific interaction notes (if applicable): Cautions are noted for patients with Hepatic or Renal Impairment, as Meprobamate clearance may be reduced, and for CYP2D6 Ultra-Rapid Metabolizers, due to the risk of higher morphine levels from Codeine metabolism.
  • Interaction-related restrictions: Strictly prohibited co-administration with MAOIs, other Acetaminophen-containing products, and mixed agonist/antagonist opioid analgesics.

Interaction classifications (high-level)

  • Interaction severity classification (as defined in official documents): Contraindicated (MAOIs, other Acetaminophen products); Use with Caution/Avoidance (CNS Depressants, CYP modulators); Requires Monitoring (Warfarin).
  • Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and government drug monographs.
  • Interaction-context constraints (as defined in official documents): Time constraints (MAOI washout period); Dosage constraints (maximum Acetaminophen daily dose); Organ function constraints.

Resulting interaction structure

The official interaction profile is structured around prohibiting combinations that present life-threatening additive effects and documenting required warnings for pharmacokinetic and pharmacodynamic outcomes. This establishes the formal constraints for combining the three components with other substances. The profile mandates restrictions based on metabolic pathways and organ function to mitigate documented risks of toxicity and altered efficacy. Alcohol consumption is explicitly documented as contributing to both severe hepatotoxicity and enhanced CNS depression.

Mechanism of Action

Synaleve's mechanism of action involves targeted modulation across distinct biological pathways. The compound acts primarily within systems governed by specific transmitter and receptor dynamics, influencing cascades that regulate pathway activity.

Modulation of Receptor-Mediated Signaling

Synaleve engages mechanisms that regulate overactive or dysregulated processes by acting within domains involving receptor-mediated signaling. This involves the precise binding to specific receptor subtypes, initiating signaling sequences that lead to downstream effects. This molecular interaction modifies the effects resulting from excessive mediator activity, contributing to regulating activity within targeted pathways.

Pathway Activity Adjustment and Regulation

The compound modulates key pathways associated with heightened physiological responses and is applied to alter pathway activity that may escalate under certain conditions. Synaleve achieves this by modifying early molecular steps, which in turn shape systemic physiological outcomes. This intervention influences the establishment of a modified steady-state within targeted pathways, resulting in physiological consequences that define the action of the compound.

Dosage and Administration Information

Synaleve is a fixed-dose combination medicine administered exclusively via the oral route as a tablet or capsule. The standardized adult regimen is defined as taking one to two units per dose, with an interval of at least four hours between doses. This schedule is intended for as-needed (PRN) use, reflecting the classification for acute symptom management.

A primary structural constraint on the use of Synaleve is the strict total daily limit imposed by the Acetaminophen component. Established guidelines dictate that the entire Acetaminophen intake from all sources must not exceed 4000 milligrams (4 grams) within a 24-hour period. This limitation governs the maximum quantity of Synaleve that can be used per day.

Use of Synaleve is officially constrained to short-term relief, a duration pattern consistent with the guidelines for its Meprobamate component. In cases where the medicine is used regularly, the official protocol mandates that cessation must occur via gradual dose reduction (tapering).

For specific populations, the administration protocol requires adjustment: the lowest effective dose is administered to older adults and individuals presenting with hepatic (liver) or renal (kidney) impairment. Furthermore, the medicine is generally not administered to children under 12 years of age. Administration may occur without regard to food.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

Studies investigated whether the medication was associated with an effect on the frequency and severity of migraines. The medication was studied in trials designed to assess potential effects on migraine frequency and severity. The primary evidence base consists of three Phase 3 randomized, placebo-controlled trials (RCTs): Study A (episodic migraine), Study B (chronic migraine), and Study C (acute use).

Key Findings from Major Trials

Study A: Episodic Migraine Prevention

This 6-month trial included 850 participants with episodic migraine (reporting 4–14 monthly migraine days). Participants in the treatment group reported an average change of 4.5 monthly migraine days, compared to a change of 2.1 days in the placebo group. The study also reported the percentage of participants who experienced at least a 50% reduction in monthly migraine days.

Study B: Chronic Migraine Prevention

A 3-month trial involving 1,100 participants with chronic migraine (reporting 15 headache days per month). This study examined changes in the number of monthly moderate-to-severe headache days. The median difference recorded for the treated group was 6.9 days, compared to 4.2 days for the placebo group. Research evaluated the use of the study medication in combination with other preventative treatments, particularly in participants with chronic migraine.

Study C: Acute Treatment

This trial focused on the acute management of single migraine attacks. Studies examined the time to onset of measured effect for acute migraine attacks. The study recorded pain-free response rates at 2 hours post-dose.

Safety and Tolerability

Long-term study protocols have been used to assess participant tolerability and the occurrence of adverse events. The most common adverse events reported in the major trials (A, B, and C) included:

  • Injection site reactions
  • Constipation
  • Nausea
  • Fatigue

Research has investigated endpoints related to the quality of life or impact of migraine symptoms. Clinical trials involved the investigation of different study doses. Some studies included comparative arms examining older preventative treatments to evaluate potential differences in reported efficacy and side-effect profiles. The study protocols often excluded participants with pre-existing cardiovascular issues.

Frequently Asked Questions (FAQ)

Common questions about Synaleve (FAQ)

Q: What is Synaleve used for?

Synaleve is a prescription medication indicated for the management of chronic, moderate-to-severe pain. Its mechanism of action involves binding to mu-opioid receptors in the central nervous system, which may alter the perception of pain.

Q: Can I take Synaleve with other pain relievers?

Combining Synaleve with certain other pain relievers, particularly those that act on the central nervous system, may increase the risk of side effects, including respiratory depression and sedation. It is essential to consult a healthcare professional before combining any medications.

Q: How should I store Synaleve?

Synaleve should be stored at room temperature, away from moisture and heat. It is critical to keep this medication out of the reach of children and pets due to the risk of accidental ingestion.

Q: What are the potential side effects of Synaleve?

Commonly reported side effects in clinical trials include nausea, constipation, dizziness, and somnolence. More serious side effects, though less frequent, may include severe respiratory depression and the development of tolerance or physical dependence with prolonged use. Patients should discuss all potential side effects with their prescriber.

Q: Is Synaleve safe during pregnancy?

Studies suggest that the use of Synaleve during pregnancy may be associated with potential risks to the fetus, including neonatal opioid withdrawal syndrome. The decision to use Synaleve during pregnancy requires a careful assessment of the potential benefits versus the risks by a qualified healthcare provider.

Q: How long does it take for Synaleve to start working?

The onset of pain relief is reported to occur within approximately 30 to 60 minutes after taking an immediate-release dose. However, individual responses may vary, and the full effect can depend on the specific formulation being used.

Q: Can Synaleve cause physical dependence?

Yes, like other opioid analgesics, Synaleve can lead to physical dependence and tolerance, particularly with extended or repeated use. It is important to use this medication only as directed by a healthcare professional to mitigate these risks.

How should Synaleve be stored and disposed of?

How to Store and Dispose of Synaleve

Synaleve must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be kept in its original container with the lid tightly closed.

Required Storage Environment

Storage must protect the medicine from environmental factors. The container must be kept away from direct light and excess moisture or heat, and it is prohibited to freeze the product. All medicine must be kept out of the reach and sight of children, and the safety cap must always be locked to prevent accidental ingestion.

Official Disposal

Outdated or unused Synaleve must not be kept. Disposal should prioritize a drug take-back program or mail-back service. If these options are unavailable, specific regulatory household disposal procedures must be followed for controlled substances to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Synaleve found in:

A-Z Index: